Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H20N6O.2ClH |
| Molecular Weight | 421.324 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.O=C(NC1=CC=CC(=C1)C2=NCCN2)NC3=CC=CC(=C3)C4=NCCN4
InChI
InChIKey=MLRXMTYSQKIKAK-UHFFFAOYSA-N
InChI=1S/C19H20N6O.2ClH/c26-19(24-15-5-1-3-13(11-15)17-20-7-8-21-17)25-16-6-2-4-14(12-16)18-22-9-10-23-18;;/h1-6,11-12H,7-10H2,(H,20,21)(H,22,23)(H2,24,25,26);2*1H
Imidocarb is a carbanilide derivative with antiprotozoal activity. It is usually administered as the dipropionate salt. Imidocarb is a drug sold under the brand name Imizol and is used to treat canine ehrlichiosis. wo mechanisms of action have been proposed:
As the effect of imidocarb on Trypanosoma brucei is antagonized by excess polyamines, it is has been suggested that imidocarb interferes with their production and/or use. Imidocarb blocks the entry of inositol into erythrocytes containing Babesia, resulting in starvation of the parasite. It is generally accepted in that imidocarb has anticholinesterase activity.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL4768 |
|||
Target ID: CHEMBL2966 |
|||
Target ID: CHEMBL220 |
590.0 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | Imizol Approved UseFor the treatment of babesiosis in dogs with clinical signs and/or demonstrated Babesia organisms in the blood. Launch Date1997 |
|||
| Curative | IMIDOCARB Approved UseFor treatment of babesiosis in cattle and horses Launch Date2001 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs. | 1992 Sep |
|
| Depletion and bioavailability of imidocarb residues in sheep and goat tissues. | 2002 Apr |
|
| In-vivo therapeutic efficacy trial with artemisinin derivative, buparvaquone and imidocarb dipropionate against Babesia equi infection in donkeys. | 2003 Nov |
|
| Concurrent bartonellosis and babesiosis in a dog with persistent thrombocytopenia. | 2003 Nov 1 |
|
| [Autochthonous babesiosis in dogs in the Netherlands?]. | 2004 May 1 |
|
| Autochthonous canine babesiosis in The Netherlands. | 2005 Jul 15 |
|
| Pharmacokinetics and mammary elimination of imidocarb in sheep and goats. | 2006 Jul |
|
| Failure of imidocarb dipropionate to clear experimentally induced Ehrlichia canis infection in dogs. | 2006 Jul-Aug |
|
| Flow cytometric evaluation of selected antimicrobial efficacy for clearance of Anaplasma marginale in short-term erythrocyte cultures. | 2006 Jun |
|
| Histological and ultrastructural studies of renal lesions in Babesia canis infected dogs treated with imidocarb. | 2007 Dec |
|
| Molecular characterisation of Babesia gibsoni infection from a pit-bull terrier pup recently imported into South Africa. | 2007 Mar |
|
| Evidence of an acute phase response in dogs naturally infected with Babesia canis. | 2007 Mar 31 |
|
| Therapeutic and prophylactic efficacy of imidocarb dipropionate on experimental Babesia ovis infection of lambs. | 2007 Oct 21 |
|
| Treatment of Mycoplasma wenyonii infection in cows with imidocarb dipropionate injection-acupuncture. | 2008 Dec |
|
| Repeated high dose imidocarb dipropionate treatment did not eliminate Babesia caballi from naturally infected horses as determined by PCR-reverse line blot hybridization. | 2008 Feb 14 |
|
| Detection of persistent Cytauxzoon felis infection by polymerase chain reaction in three asymptomatic domestic cats. | 2008 Jul |
|
| An unusual form of canine babesiosis. | 2008 Mar |
|
| Ultrastructural and fluorochromatic changes of Anaplasma marginale exposed to oxytetracycline, imidocarb and enrofloxacin in short-term erythrocyte cultures. | 2009 Apr 14 |
|
| Alterations in some blood coagulation parameters in naturally occurring cases of canine babesiosis. | 2009 Jun |
|
| Rocky Mountain spotted fever in dogs, Brazil. | 2009 Mar |
|
| Detection of Babesia divergens in southern Norway by using an immunofluorescence antibody test in cow sera. | 2010 Oct 6 |
Sample Use Guides
Use intramuscularly or subcutaneously at a rate of 6.6 mg/kg (3 mg/lb) body weight. Repeat the dose in two (2) weeks, for a total of two (2) treatments.
Route of Administration:
Other
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C277
Created by
admin on Fri Dec 15 15:21:23 GMT 2023 , Edited by admin on Fri Dec 15 15:21:23 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID30201240
Created by
admin on Fri Dec 15 15:21:23 GMT 2023 , Edited by admin on Fri Dec 15 15:21:23 GMT 2023
|
PRIMARY | |||
|
300000023746
Created by
admin on Fri Dec 15 15:21:23 GMT 2023 , Edited by admin on Fri Dec 15 15:21:23 GMT 2023
|
PRIMARY | |||
|
m6226
Created by
admin on Fri Dec 15 15:21:23 GMT 2023 , Edited by admin on Fri Dec 15 15:21:23 GMT 2023
|
PRIMARY | Merck Index | ||
|
C76422
Created by
admin on Fri Dec 15 15:21:23 GMT 2023 , Edited by admin on Fri Dec 15 15:21:23 GMT 2023
|
PRIMARY | |||
|
CHEMBL427342
Created by
admin on Fri Dec 15 15:21:23 GMT 2023 , Edited by admin on Fri Dec 15 15:21:23 GMT 2023
|
PRIMARY | |||
|
226-179-7
Created by
admin on Fri Dec 15 15:21:23 GMT 2023 , Edited by admin on Fri Dec 15 15:21:23 GMT 2023
|
PRIMARY | |||
|
51189
Created by
admin on Fri Dec 15 15:21:23 GMT 2023 , Edited by admin on Fri Dec 15 15:21:23 GMT 2023
|
PRIMARY | |||
|
21388
Created by
admin on Fri Dec 15 15:21:23 GMT 2023 , Edited by admin on Fri Dec 15 15:21:23 GMT 2023
|
PRIMARY | |||
|
KCC1V76AH8
Created by
admin on Fri Dec 15 15:21:23 GMT 2023 , Edited by admin on Fri Dec 15 15:21:23 GMT 2023
|
PRIMARY | |||
|
5318-76-3
Created by
admin on Fri Dec 15 15:21:23 GMT 2023 , Edited by admin on Fri Dec 15 15:21:23 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
